SCHEMBL1994093

SCHEMBL1994093

CC(C)(C)Cn1nnc2ccc(O)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.40
KMO O15229 1/20 0.38
ATM Q13315 1/20 0.38
SLC9A1 P19634 3/20 0.38
TDO2 P48775 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
KMT2A Q03164 1/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
TLR9 Q9NR96 1/20 0.37
KCNMA1 Q12791 1/20 0.36
AR P10275 1/20 0.35
MGAM O43451 2/20 0.35
AMY1A P0DUB6 2/20 0.35
GAA P10253 2/20 0.35
SI P14410 2/20 0.35
MGAM2 Q2M2H8 2/20 0.35
HCAR3 P49019 1/20 0.34
ESR1 P03372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001605 0.87 HCAR3 (0.43) RPS6KA3ATMSLC9A1TDO2KCNMA1
SCHEMBL11955094 0.76 SLC9A1 (0.65) ATMSLC9A1KEAP1KCNMA1MGAM
SCHEMBL20529702 0.73 TDO2 (0.56) RPS6KA3KMOTDO2MGAMAMY1A
SCHEMBL30699124 0.72 AR (0.40) KMOATMSLC9A1TDO2AR
SCHEMBL27038551 0.72 AR (0.40) KMOATMSLC9A1TDO2AR
SCHEMBL3192611 0.72 KEAP1 (0.53) SLC9A1MEN1USP2KMT2AKEAP1
SCHEMBL3475150 0.71 KDM4E (0.46) SLC9A1TDO2GAAHCAR3
SCHEMBL26777187 0.71 PKM (0.41) ATMSLC9A1TDO2HCAR3HTR1D
SCHEMBL22155665 0.70 MGAM (0.38) KMOATMSLC9A1TDO2AR
SCHEMBL6044297 0.70 HCAR3 (0.72) HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960417-B2 Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders MERCK SHARP & DOHME CORP. (US) 2011-06-14 US disclosed
US-20080176904-A1 Benzazole Potentiators of Metabotropic Glutatmate Receptors MERCK SHARP & DOHME CORP. 2008-07-24 US disclosed
EP-1855670-A2 BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merck & Co., Inc. (US) 2007-11-21 EP disclosed
WO-2006091496-A2 BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176904-A1 Benzazole Potentiators of Metabotropic Glutatmate Receptors GRM2, GRM3, GRIK2 RPS6KA3 2515/4885KMO 924/4885ATM 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.